Array Biopharma (ARRY) Says Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median OS in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial
Tweet Send to a Friend
Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced results of the planned ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
